Key result
MitraClip implantation reduced mean left atrial V-wave from 46.67 to 21.67 mmHg and improved MR grade in critically ill patients with refractory heart failure.
Why the study?
The role of MitraClip implantation in the treatment of critically ill patients with heart failure and severe functional mitral regurgitation is undetermined.
Does MitraClip implantation improve outcomes in critically ill patients with refractory heart failure and severe functional mitral regurgitation?
Observational (n=6)
No
Does MitraClip implantation improve outcomes in critically ill patients with refractory heart failure and severe functional mitral regurgitation?
MitraClip therapy may be a feasible bail-out option for critically ill patients with refractory heart failure and severe functional mitral regurgitation, improving hemodynamics and facilitating weaning from intravenous and mechanical support.
Answers are grounded in this paper and cite their sources.
May support bailout MitraClip use in refractory HF with severe FMR; leaves open need for prospective trials.
BackgroundThe role of the MitraClip implantation in treatment of critically ill patients with heart failure and severe functional mitral regurgitation is undetermined.MethodsWe screened all patients who underwent MitraClip implantation at the Hadassah Medical Center between October 2015 and December 2017. We evaluated immediate, 30-day and 1-year outcomes after the procedure in patients with refractory heart failure and severe functional mitral regurgitation, including patients with acute ischemic mitral regurgitation.ResultsFrom a cohort of 64 patients, who underwent MitraClip implantation in our center, we identified six critically ill patients (9.4%) with decompensated refractory heart failure and severe functional mitral regurgitation (4+). Patients’ mean age was 69.2 years, 67% were males. One, 2, or 3 clips were implanted in each case. Reduction of mitral regurgitation from grade 4+ to 1+ was achieved in 3 patients (50%), to grade 2+ in 2 patients (33.3%) with significant mean reduction of left atrial V-wave from 46.67 ± 8.50 mmHg to 21.67 ± 6.14 mmHg (p = 0.009). Five patients were weaned from intravenous therapy and intra-aortic balloon pump support 24–72 hours after the procedure. One patient died during hospitalization due to sepsis. Thirty-day follow-up analysis showed improvement of NYHA functional class.ConclusionsMitraClip therapy could be a “bail-out” option in treatment of critically ill patients with refractory heart failure and severe functional mitral regurgitation.
No takes yet. Share an insight, caveat, or question.
Medvedovsky et al. (2019) conducted an observational in Decompensated refractory heart failure and severe functional mitral regurgitation (n=6). MitraClip implantation was evaluated on Reduction of mitral regurgitation and left atrial V-wave (p=0.009). MitraClip implantation reduced mean left atrial V-wave from 46.67 to 21.67 mmHg and improved MR grade in critically ill patients with refractory heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: